kidney pelvis papillary carcinoma

Kidney Pelvis Papillary Carcinoma: An Overview

Papillary renal cell carcinoma (PRCC) is a type of cancer that affects the kidneys, specifically forming in the lining of the tiny tubes in the kidney that filter waste products from the blood. This condition is also known as papillary carcinoma of the renal pelvis.

Characteristics and Types

There are two types of PRCC: Type 1 and Type 2. Most papillary tumors look like long, thin finger-like growths under a microscope [1]. These cancers form little finger-like projections (called papillae) in the tubules of the kidneys [12].

Symptoms and Treatment

Common symptoms of PRCC include blood in the urine, pain, and feeling a mass in your side [13]. Papillary renal cell carcinoma is usually treated with surgery [13].

Prevalence and Subtypes

Papillary renal cell carcinoma accounts for approximately 15-20% of all renal cell carcinomas (RCCs) in adults [10][11]. The most common subtypes of RCC are clear cell RCC, papillary RCC, and chromophobe RCC [15].

Note: The information provided is based on the search results and may not be an exhaustive or definitive description of kidney pelvis papillary carcinoma.

Common Signs and Symptoms

Kidney pelvis papillary carcinoma, also known as renal pelvic cancer or transitional cell cancer, can exhibit several signs and symptoms. These may include:

• Blood in the urine: This is often the most common symptom, which can be visible to the naked eye or only detectable through a urinalysis test [1][2][3].
• Persistent back pain: Pain in the lower back that persists over time can be an indication of kidney pelvis papillary carcinoma [4][5].
• Fatigue: Feeling tired or weak for no apparent reason can also be a symptom

Diagnostic Tests for Kidney Pelvis Papillary Carcinoma

Papillary renal cell carcinoma (PRCC) is a type of cancer that affects the kidneys, and diagnosing it requires a combination of physical examination, medical history, laboratory tests, and imaging studies. Here are some diagnostic tests used to identify PRCC:

• Imaging tests: These include:
  • Computed Tomography (CT) scans: CT scans can help identify tumors in the kidney and surrounding areas [10].
  • Magnetic Resonance Imaging (MRI): MRI scans can provide detailed images of the kidneys, ureters, and bladder [1].
  • Ultrasound: Ultrasound imaging can be used to guide a biopsy needle into a suspected area of cancer in the abdomen or pelvis [3].
• Laboratory tests: These include:
  • Blood work: Comprehensive blood work is typically obtained to rule out other conditions that may cause similar symptoms [12].
  • Urinalysis: A test to check the color and contents of urine, such as sugar, protein, and blood [2].
• Biopsy: A biopsy involves taking a sample of kidney tissue for examination under a microscope. This is usually done after imaging tests have identified a tumor in the kidney [13].

Staging Tests

Once PRCC has been diagnosed, staging tests are used to determine the extent of cancer spread. These may include:

• Additional CT and MRI scans: To assess the size and location of tumors in the kidneys and surrounding areas [15].
• Bone scans: To check for any signs of cancer spread to the bones.
• Evaluations of the brain: Depending on symptoms and initial study results.

It's essential to note that a combination of these diagnostic tests is usually necessary to confirm a diagnosis of PRCC. A healthcare provider will determine which tests are needed based on individual circumstances.

References:

[1] Mar 22, 2024 — An ultrasound of the abdomen may be done to help diagnose cancer of the renal pelvis and ureter. [2] How do healthcare

Differential Diagnosis of Kidney Pelvis Papillary Carcinoma

Papillary urothelial carcinomas of the renal pelvis and ureter can be challenging to diagnose, as they may resemble other types of tumors or conditions. The differential diagnosis for these cancers includes:

• Metastatic papillary serous carcinoma: This type of cancer is more common in women and can metastasize to the peritoneum, abdominal lymph nodes, and mesentery.
• Renal cell carcinoma (RCC): RCC is the most common malignant renal tumor, accounting for approximately 85% of all kidney cancers. However, it typically occurs in a different location within the kidney.
• Papillary renal cell carcinoma: This type of cancer is the second most common malignant renal epithelial tumor and can be mistaken for papillary urothelial carcinomas due to its similar appearance.
• Mucinous tubular and spindle cell carcinoma (MTSCC): MTSCC is a rare type of RCC that can be difficult to distinguish from papillary urothelial carcinomas.
• Clear cell papillary RCC (ccpRCC): ccpRCC is another subtype of RCC that can be mistaken for papillary urothelial carcinomas due to its similar histological features.

Key Points

• Papillary urothelial carcinomas of the renal pelvis and ureter are rare, accounting for approximately 10% of all renal tumors.
• The main differential diagnosis for these cancers includes metastatic papillary serous carcinoma, RCC, papillary renal cell carcinoma, MTSCC, and ccpRCC.
• Accurate diagnosis requires a combination of clinical presentation, imaging studies, and histopathological examination.

References

[1] Urothelial cancers of the renal pelvis and collecting system constitute approximately 10%–15% of all renal tumors: 90% are transitional cell carcinoma (TCC), 9% are squamous cell carcinoma, and 1% are mucinous adenocarcinoma.[7 8]

[2] The main differential diagnosis in women is with a metastatic papillary serous carcinoma, especially if the tumor is originally discovered in the peritoneum, abdominal lymph nodes and mesentery or ...

[3] Papillary renal cell carcinoma is the second most common malignant renal epithelial tumor and constitutes approximately 15% of renal cell tumors. However, papillary architecture is neither unique to papillary renal cell carcinoma, nor do all papillary renal cell carcinomas show exclusive papillary histology.

[4] Renal cell carcinomas (RCC) are primary malignant adenocarcinomas derived from the renal tubular epithelium and are the most common malignant renal tumor.